Roxbury Financial LLC Acquires Shares of 753 Natera, Inc. (NASDAQ:NTRA)

Roxbury Financial LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 753 shares of the medical research company’s stock, valued at approximately $126,000.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. increased its position in shares of Natera by 223.7% during the fourth quarter. Blue Trust Inc. now owns 301 shares of the medical research company’s stock valued at $48,000 after buying an additional 208 shares during the period. Chevy Chase Trust Holdings LLC grew its stake in shares of Natera by 14.4% in the fourth quarter. Chevy Chase Trust Holdings LLC now owns 549,871 shares of the medical research company’s stock worth $87,045,000 after acquiring an additional 69,129 shares during the last quarter. Compagnie Lombard Odier SCmA bought a new position in shares of Natera in the fourth quarter worth approximately $206,000. Van ECK Associates Corp raised its stake in shares of Natera by 17.4% in the fourth quarter. Van ECK Associates Corp now owns 119,673 shares of the medical research company’s stock worth $18,944,000 after purchasing an additional 17,748 shares during the last quarter. Finally, Gladstone Institutional Advisory LLC lifted its holdings in shares of Natera by 1.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock valued at $574,000 after buying an additional 61 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 4,858 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $166.59, for a total value of $809,294.22. Following the completion of the sale, the insider now directly owns 114,912 shares of the company’s stock, valued at approximately $19,143,190.08. This represents a 4.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 305,454 shares of company stock worth $51,290,625. 7.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on NTRA. Sanford C. Bernstein increased their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Guggenheim increased their price target on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. JPMorgan Chase & Co. raised their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Finally, Canaccord Genuity Group raised their price target on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $165.88.

Natera Price Performance

NASDAQ:NTRA opened at $173.39 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company’s 50-day moving average price is $167.75 and its 200-day moving average price is $142.83. Natera, Inc. has a twelve month low of $68.03 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the prior year, the business earned ($0.95) EPS. The firm’s quarterly revenue was up 63.9% on a year-over-year basis. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.